Role of soluble guanylyl cyclase in renal afferent and efferent arterioles

Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F193-F202. doi: 10.1152/ajprenal.00272.2020. Epub 2020 Dec 28.

Abstract

Renal arteriolar tone depends considerably on the dilatory action of nitric oxide (NO) via activation of soluble guanylyl cyclase (sGC) and cGMP action. NO deficiency and hypoxia/reoxygenation are important pathophysiological factors in the development of acute kidney injury. It was hypothesized that the NO-sGC-cGMP system functions differently in renal afferent arterioles (AA) compared with efferent arterioles (EA) and that the sGC activator cinaciguat differentially dilates these arterioles. Experiments were performed in isolated, perfused mouse glomerular arterioles. Hypoxia (0.1% oxygen) was achieved by using a hypoxia chamber. Phosphodiesterase 5 (PDE5) and sGC subunits were considerably expressed on the mRNA level in AA. PDE5 inhibition with sildenafil, which blocks cGMP degradation, diminished the responses to ANG II bolus application in AA, but not significantly in EA. Vasodilation induced by sildenafil in ANG II-preconstricted vessels was stronger in EA than AA. Cinaciguat, an NO- and heme-independent sGC activator, dilated EA more strongly than AA after NG-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor) treatment and preconstriction with ANG II. Cinaciguat-induced dilatation of l-NAME-pretreated and ANG II-preconstricted arterioles was similar to controls without l-NAME treatment. Cinaciguat also induced dilatation in iodinated contrast medium treated AA. Furthermore, it dilated EA, but not AA, after hypoxia/reoxygenation. The results reveal an important role of the NO-sGC-cGMP system for renal dilatation and that EA have a more potent sGC activated dilatory system. Furthermore, AA seem to be more sensitive to hypoxia/reoxygenation than EA under these experimental conditions.

Keywords: acute kidney injury; afferent arteriole; efferent arteriole; hypoxia/reoxygenation; phosphodiesterase; soluble guanylyl cyclase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Arterioles / enzymology*
  • Arterioles / physiology
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / genetics
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Expression Regulation, Enzymologic / physiology
  • Kidney / blood supply*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide
  • Phosphodiesterase 5 Inhibitors / pharmacology
  • Soluble Guanylyl Cyclase / genetics
  • Soluble Guanylyl Cyclase / metabolism*

Substances

  • Phosphodiesterase 5 Inhibitors
  • Angiotensin II
  • Nitric Oxide
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Soluble Guanylyl Cyclase
  • NG-Nitroarginine Methyl Ester